Keywords: vascular softening, softening vessels, cerebral ischemia, lacunar infarction, ischemic stroke, myocardial ischemia, angina pectoris, cardiac infarction, consolidated kidneys, intermittent claudication, diabetic foot, atherosclerosis, vascular occlusion, aspirin, urokinase, warfarin, cilostazol, platelet aggregation, thrombolysis, thrombolytic, coronary artery disease, cardiac myocardial atrophy, intermittent claudication, atherosclerotic plaques, ankle-arm index , angiography. Vascular softening vascular problems should be possible in principle. Its theoretical basis has two: from a philosophical point of view: any contradictory sides are able to transform each other, but there must be certain conditions; from the perspective of basic medicine: whether theoretical or animal experiments or clinical have a lot of discussion and specific facts prove that the hardened blood vessels can be softened. However, in the actual clinical work, the problem of vascular softening is a world problem. Thus, the softening of blood vessels has become the current hot topic of cardiovascular and cerebrovascular disease, the reason for this is that the “three highs” is the ultimate danger of vascular sclerosis (pathology), normal people old, blood vessels should also be hardened (physiological). Cerebral ischemia (chronic dizziness, cava infarction, ischemic stroke), myocardial ischemia (angina pectoris, cardiac infarction), renal ischemia (hypertension contraction of the kidneys, diabetic nephropathy), ischemia of the limbs (intermittent claudication, diabetic foot, dry necrosis of the toes), etc., is hardening of the arteries, vascular occlusion of the reason. In this regard, general Western drugs (such as aspirin, urokinase, warfarin, cilostazol, etc.) can only prevent platelet aggregation or make the thrombus formed within 2 to 4 hours (thrombolytic effect), but the hardened blood vessel wall is ineffective; similarly, all antihypertensive drugs are only effective in the non-hardened blood vessels, so that the dilation of the blood pressure drop; most of the single-flavored traditional Chinese medicines and compounded Chinese traditional Chinese medicine to activate blood circulation and remove blood stasis (eg, blood circulation tablets, pulsatile capsules, cardioplegic capsules, cardioplegia), and so on. Most of the single-flavored Chinese medicines and compound Chinese medicines (such as blood circulation tablets, pulsatilla capsule, cardio-cerebral blood circulation Kang, Tongxinluo capsule, hematocrit tablets, Tongxinling capsule, cardio-pulmonary tablets, compound danshen tablets and so on) can only soften part of the coagulated blood or thrombus formation, but not soften the blood vessels. Because many chronic dizziness has been CT proved to be caused by cerebral ischemia, with flunarizine, blood circulation tablets and other Chinese and Western medicines, can only be some relief after taking medication, but a stop, time soon symptoms recur, the same angina pectoris is still serious to be installed with a stent, intermittent claudication of lower limbs drug therapy is ineffective for dry necrosis of the toes is ineffective, generally mobilized to install the stent or amputation of the patient. This shows that most of the current use of Chinese and Western drugs for atherosclerosis caused by organs and tissues ischemia treatment effect is limited, the role of softening blood vessels is even more minimal. If the use of a drug or a compound can make the patient to achieve the following effects, it should be considered that the drug or compound has the function of softening blood vessels. 1, the drug or compound can significantly improve the patient ischemic cerebrovascular disease, coronary heart disease (infarction, angina pectoris, ischemic myocardial atrophy), lower extremity atherosclerosis caused by intermittent claudication, necrosis of the toes and other symptoms, and stopping the drug for a long time (at least more than three months) to maintain the effect of treatment; 2, the drug or compound can make patients with high blood pressure, in the service of blood pressure-lowering drugs remain unchanged, the blood pressure compared to the previous situation, there is a significant (10-20) mmHg) drop (especially in the blood pressure of the patient). The drug or compound can make patients with hypertension have a significant (10~20mmHg) drop in blood pressure (especially systolic blood pressure), and the efficacy can be maintained for a long time after stopping the drug; 3. Auxiliary examinations have been verified: myocardial ischemia: T wave is low, inverted, and begins to approach the normal wave; renal insufficiency: creatinine and urea nitrogen drop significantly and tend to be normal; lower limb ischemia: ultrasound: it shows that atherosclerotic plaques of the lower limbs have the evidence of shrinkage or disappearance of the image; angiography shows that the proportion of stenosis shrinks, and the blood flow is reduced. The proportion of stenosis is reduced and blood flow is improved. 4. Rising/near-normal ankle/arm index (i.e., rising arterial blood pressure in the lower extremities). The use of this drug or compound for the treatment of cerebral ischemic vascular disease due to atherosclerosis, coronary heart disease (heart attack, angina pectoris, ischemic cardiac atrophy), intermittent claudication due to lower extremity atherosclerosis, and necrosis of the toes, etc., should have a significant and long-lasting effect. I am trying to do exploration in this area and seem to see a little light in some cases.